Clinical Trials Logo

Clinical Trial Summary

In this study subjects self recorded nasal and ocular symptoms scores from exposure to ragweed pollen in an Allergen Challenge Chamber (ACC). This single site study of seasonal allergic rhinitis was designed to enroll up to 35 participants. These participants would be age 18-70, male and female, with a mixture of ethnic groups. The study would involve 2 phases: Screening and Exposure. In the Exposure phase, participants were exposed to pollen for up to 180 minutes.


Clinical Trial Description

This was a study to evaluate self recorded nasal and ocular allergy symptom scores from exposure to ragweed pollen in an Allergen Challenge Chamber (ACC). This single site study of seasonal allergic rhinitis was designed to enroll up to 35 participants. These participants would be age 18-70, male and female, with a mixture of ethnic groups. The study would involve 2 phases: Screening and Exposure. In the Exposure phase, participants were exposed to pollen for up to 180 minutes. For allergic participants, qualification symptom scores at 120 minutes of exposure determined if ACC exposure would be continued. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03496103
Study type Interventional
Source The University of Texas Medical Branch, Galveston
Contact
Status Completed
Phase Phase 1
Start date February 29, 2016
Completion date March 12, 2016

See also
  Status Clinical Trial Phase
Recruiting NCT03363698 - MCT and Capsaicin Provocation Challenge in Diagnosis of Chronic Cough N/A
Active, not recruiting NCT03644680 - Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study N/A
Not yet recruiting NCT03636919 - Component Resolved Diagnostics (CRD) and mHealth for Pollen Allergy In Southern Europe.
Enrolling by invitation NCT02910401 - Clinical Response to Rhinovirus Challenge Phase 2
Not yet recruiting NCT01014325 - Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy Phase 3
Completed NCT02943720 - ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen Phase 2
Completed NCT02556801 - SUBLIVAC Phleum Study Phase 2
Not yet recruiting NCT02233426 - Effect of Hypertonic Solutions on Allergic Rhinitis Patients N/A
Completed NCT02352168 - Airway Inflammation in Children With Allergic Rhinitis and Intervention N/A
Completed NCT01918956 - PURETHAL Birch RUSH Study Phase 4
Completed NCT01946035 - Alpha-Blockers in Allergic Rhinitis (MAN 01) Phase 4
Completed NCT01682070 - SUBLIVAC FIX Phleum Pratense DT/DRF Phase 2
Recruiting NCT01454492 - The Relationship Between Allergic Rhinitis and Geographic Tongue N/A
Completed NCT01438463 - PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis Phase 2
Completed NCT01439815 - An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Phase 4
Completed NCT01185080 - Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848 Phase 2
Completed NCT01471184 - The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo Phase 1
Completed NCT00698594 - Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis Phase 4
Completed NCT00770003 - Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848 Phase 1
Completed NCT00758446 - Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis Phase 2